Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reporting colorectal cancer.

P Quirke1, E Morris

  • 1Leeds Institute of Molecular Medicine, University of Leeds, St James's University Hospital and Department of Histopathology and Molecular Pathology, Institute of Pathology, Leeds General Infirmary, Leeds, UK. patpq@leeds.ac.uk

Histopathology
|January 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymph node mapping-based optimal bowel-resection margin and central radicality in colon cancer surgery: an international, prospective, observational cohort study.

ESMO gastrointestinal oncology·2026
Same author

Corrigendum to "Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population": [Ann Oncol 36 (2025) 520-528].

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion.

Translational oncology·2024
Same author

The gut microbiota in adults with cystic fibrosis compared to colorectal cancer.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.

British journal of haematology·2023
Same journal

TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma.

Histopathology·2026
Same journal

Malignant adenomyoepithelioma of the breast: seven cases illustrating morphological diversity and diagnostic challenges.

Histopathology·2026
Same journal

A CRX-positive RB1-deficient bone tumour with a retinoblastoma-like DNA methylation profile.

Histopathology·2026
Same journal

Perivascular epithelioid cell tumours of the genitourinary tract: clinicopathological features and molecular landscape.

Histopathology·2026
Same journal

Navigating diagnostic challenges in low-grade spindle cell lesions of the breast: a retrospective review.

Histopathology·2026
Same journal

Neoplastic transformation of sporadic gastric hyperplastic polyps: a systematic review and meta-analysis of risk factors and clinicopathological features.

Histopathology·2026
See all related articles

Accurate colorectal cancer reporting by pathologists is crucial for effective treatment. Standardized reporting, focusing on key features like circumferential resection margin, improves patient care and treatment decisions.

Area of Science:

  • Oncology
  • Pathology
  • Surgical Oncology

Background:

  • Colorectal cancer management is a collaborative team effort.
  • Pathologist's accurate reporting is vital for guiding treatment decisions.
  • Incomplete reporting can lead to suboptimal patient management.

Purpose of the Study:

  • To emphasize the critical role of pathological reporting in colorectal cancer management.
  • To highlight key prognostic features for accurate staging and treatment planning.
  • To recommend specific reporting standards for improved reproducibility and patient outcomes.

Main Methods:

  • Review of essential pathological features for colorectal cancer staging.
  • Evaluation of prognostic indicators in Stage II/Dukes' B colorectal cancer.

Related Experiment Videos

  • Assessment of the value of the circumferential resection margin (CRM) post-neoadjuvant therapy.

    • Main Results:

    • Key features for Stage II/Dukes' B include extramural vascular invasion, peritoneal involvement, extent of spread, incomplete resection, and perforation.
    • Circumferential resection margin (CRM) is a significant prognostic factor, retaining value after preoperative therapy.
    • Standardized dissection, sampling, and regression grading are essential for reliable reporting.

    Conclusions:

    • High-quality pathological reporting is fundamental for optimal colorectal cancer management.
    • Adherence to specific reporting guidelines and features ensures appropriate adjuvant therapy administration.
    • Standardization of pathological assessment is necessary for consistent clinical trial and center-based comparisons.